The rise of Sildenafil initially sparked a period of growth for the drug industry, nevertheless recent shifts present a uncertain picture for shareholders. Off-patent versions are eating into earnings, and continued https://dillanuijn916145.madmouseblog.com/21916530/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-investment